Summary

Metastatic Bone Disease Market – Scope of Report
TMR’s report on the global metastatic bone disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global metastatic bone disease market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global metastatic bone disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the metastatic bone disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global metastatic bone disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global metastatic bone disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global metastatic bone disease market.

The report delves into the competitive landscape of the global metastatic bone disease market. Key players operating in the global metastatic bone disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global metastatic bone disease market profiled in this report.

Key Questions Answered in Global metastatic bone disease Market Report
• What is the sales/revenue generated by metastatic bone disease across all regions during the forecast period?
• What are the opportunities in the global metastatic bone disease market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Metastatic Bone Disease Market – Research Objectives and Research Approach
The comprehensive report on the global metastatic bone disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global metastatic bone disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global metastatic bone disease market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Metastatic Bone Disease Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Metastatic Bone Disease Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Metastatic Bone Disease Market Analysis and Forecast, by Treatment
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Medication
6.3.1.1. Chemotherapy
6.3.1.2. Hormone Therapy
6.3.1.3. Bisphosphonates
6.3.1.4. Opiate Therapy
6.3.1.5. Immunotherapy
6.3.2. Radiation Therapy
6.3.3. Surgical Intervention
6.3.4. Tumor Ablation Therapy
6.4. Market Attractiveness, by Treatment
7. Global Metastatic Bone Disease Market Analysis and Forecast, by Origin of Metastasis
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Origin of Metastasis, 2017–2031
7.3.1. Breast
7.3.2. Lung
7.3.3. Thyroid
7.3.4. Kidney
7.3.5. Prostate
7.3.6. Others
7.4. Market Attractiveness, by Origin of Metastasis
8. Global Metastatic Bone Disease Market Analysis and Forecast, by Provider Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Provider Type, 2017–2031
8.3.1. OEM
8.3.2. Non-OEM
8.4. Market Attractiveness, by Provider Type
9. Global Metastatic Bone Disease Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Ambulatory Surgical Centers
9.4. Market Attractiveness, by End-user
10. Global Metastatic Bone Disease Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Metastatic Bone Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2031
11.2.1. Medication
11.2.1.1. Chemotherapy
11.2.1.2. Hormone Therapy
11.2.1.3. Bisphosphonates
11.2.1.4. Opiate Therapy
11.2.1.5. Immunotherapy
11.2.2. Radiation Therapy
11.2.3. Surgical Intervention
11.2.4. Tumor Ablation Therapy
11.3. Market Attractiveness, by Treatment
11.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
11.4.1. Breast
11.4.2. Lung
11.4.3. Thyroid
11.4.4. Kidney
11.4.5. Prostate
11.4.6. Others
11.5. Market Attractiveness, by Origin of Metastasis
11.6. Market Value Forecast, by Provider Type, 2017–2031
11.6.1. OEM
11.6.2. Non-OEM
11.7. Market Attractiveness, by Provider Type
11.8. Market Value Forecast, by End-user
11.8.1. Hospitals
11.8.2. Specialty Clinics
11.8.3. Ambulatory Surgical Centers
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Treatment
11.11.2. By Origin of Metastasis
11.11.3. By Provider Type
11.11.4. By End-user
11.11.5. By Country
12. Europe Metastatic Bone Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2031
12.2.1. Medication
12.2.1.1. Chemotherapy
12.2.1.2. Hormone Therapy
12.2.1.3. Bisphosphonates
12.2.1.4. Opiate Therapy
12.2.1.5. Immunotherapy
12.2.2. Radiation Therapy
12.2.3. Surgical Intervention
12.2.4. Tumor Ablation Therapy
12.3. Market Attractiveness, by Treatment
12.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
12.4.1. Breast
12.4.2. Lung
12.4.3. Thyroid
12.4.4. Kidney
12.4.5. Prostate
12.4.6. Others
12.5. Market Attractiveness, by Origin of Metastasis
12.6. Market Value Forecast, by Provider Type, 2017–2031
12.6.1. OEM
12.6.2. Non-OEM
12.7. Market Attractiveness, by Provider Type
12.8. Market Value Forecast, by End-user, 2017–2031
12.8.1. Hospitals
12.8.2. Specialty Clinics
12.8.3. Ambulatory Surgical Centers
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Treatment
12.11.2. By Origin of Metastasis
12.11.3. By Provider Type
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Metastatic Bone Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2031
13.2.1. Medication
13.2.1.1. Chemotherapy
13.2.1.2. Hormone Therapy
13.2.1.3. Bisphosphonates
13.2.1.4. Opiate Therapy
13.2.1.5. Immunotherapy
13.2.2. Radiation Therapy
13.2.3. Surgical Intervention
13.2.4. Tumor Ablation Therapy
13.3. Market Attractiveness, by Treatment
13.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
13.4.1. Breast
13.4.2. Lung
13.4.3. Thyroid
13.4.4. Kidney
13.4.5. Prostate
13.4.6. Others
13.5. Market Attractiveness, by Origin of Metastasis
13.6. Market Value Forecast, by Provider Type, 2017–2031
13.6.1. OEM
13.6.2. Non-OEM
13.7. Market Attractiveness, by Provider Type
13.8. Market Value Forecast, by End-user, 2017–2031
13.8.1. Hospitals
13.8.2. Specialty Clinics
13.8.3. Ambulatory Surgical Centers
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Treatment
13.11.2. By Origin of Metastasis
13.11.3. By Provider Type
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Metastatic Bone Disease Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017–2031
14.2.1. Medication
14.2.1.1. Chemotherapy
14.2.1.2. Hormone Therapy
14.2.1.3. Bisphosphonates
14.2.1.4. Opiate Therapy
14.2.1.5. Immunotherapy
14.2.2. Radiation Therapy
14.2.3. Surgical Intervention
14.2.4. Tumor Ablation Therapy
14.3. Market Attractiveness, by Treatment
14.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
14.4.1. Breast
14.4.2. Lung
14.4.3. Thyroid
14.4.4. Kidney
14.4.5. Prostate
14.4.6. Others
14.5. Market Attractiveness, by Origin of Metastasis
14.6. Market Value Forecast, by Provider Type, 2017–2031
14.6.1. OEM
14.6.2. Non-OEM
14.7. Market Attractiveness, by Provider Type
14.8. Market Value Forecast, by End-user, 2017–2031
14.8.1. Hospitals
14.8.2. Specialty Clinics
14.8.3. Ambulatory Surgical Centers
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Treatment
14.11.2. By Origin of Metastasis
14.11.3. By Provider Type
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Metastatic Bone Disease Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment, 2017–2031
15.2.1. Medication
15.2.1.1. Chemotherapy
15.2.1.2. Hormone Therapy
15.2.1.3. Bisphosphonates
15.2.1.4. Opiate Therapy
15.2.1.5. Immunotherapy
15.2.2. Radiation Therapy
15.2.3. Surgical Intervention
15.2.4. Tumor Ablation Therapy
15.3. Market Attractiveness, by Treatment
15.4. Market Value Forecast, by Origin of Metastasis, 2017–2031
15.4.1. Breast
15.4.2. Lung
15.4.3. Thyroid
15.4.4. Kidney
15.4.5. Prostate
15.4.6. Others
15.5. Market Attractiveness, by Origin of Metastasis
15.6. Market Value Forecast, by Provider Type, 2017–2031
15.6.1. OEM
15.6.2. Non-OEM
15.7. Market Attractiveness, by Provider Type
15.8. Market Value Forecast, by End-user, 2017–2031
15.8.1. Hospitals
15.8.2. Specialty Clinics
15.8.3. Ambulatory Surgical Centers
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Treatment
15.11.2. By Origin of Metastasis
15.11.3. By Provider Type
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Amgen, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Merck & Co., Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Novartis AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Eli Lilly and Company
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Bayer AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Fresenius Kabi AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Boston Scientific Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Medtronic
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview